Effect of Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin on Plasminogen Activator Inhibitor-1 in Patients With Diabetes Mellitus

Dipeptidyl peptidase-4 (DPP-4) inhibitors may affect the serum levels of plasminogen activator inhibitor-1 (PAI-1) associated with triglyceride (TG) metabolism, which is a prognostic factor for cardiovascular disease, in diabetic patients. We conducted an 8-week, prospective, randomized study in whi...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2015-02, Vol.115 (4), p.454-460
Main Authors: Tani, Shigemasa, MD, Takahashi, Atsuhiko, MD, Nagao, Ken, MD, Hirayama, Atsushi, MD
Format: Article
Language:English
Subjects:
Adamantane - administration & dosage
Adamantane - analogs & derivatives
Adipocytes
Aged
Apolipoproteins
Blood Glucose - metabolism
Cardiovascular
Cardiovascular disease
Cardiovascular Diseases - blood
Cardiovascular Diseases - complications
Cardiovascular Diseases - drug therapy
Cholesterol
Diabetes
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Dipeptidyl-Peptidase IV Inhibitors - administration & dosage
Drug use
Female
Follow-Up Studies
Glycated Hemoglobin A - metabolism
Heart attacks
Homeostasis
Humans
Hypertension
Insulin
Insulin resistance
Lipids
Low density lipoprotein
Male
Metabolism
Middle Aged
Nitriles - administration & dosage
Particle size
Physiology
Plasminogen Activator Inhibitor 1 - blood
Prospective Studies
Pyrrolidines - administration & dosage
Regression analysis
Substance abuse treatment
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dipeptidyl peptidase-4 (DPP-4) inhibitors may affect the serum levels of plasminogen activator inhibitor-1 (PAI-1) associated with triglyceride (TG) metabolism, which is a prognostic factor for cardiovascular disease, in diabetic patients. We conducted an 8-week, prospective, randomized study in which we assigned type 2 diabetic patients who were inadequately controlled with antidiabetic therapy to the vildagliptin group (50 mg bid, n = 49) or the control group (n = 49). The primary efficacy parameter was the change in the serum level of PAI-1, and the secondary end point was the change in the serum levels of TG-rich lipoproteins. In the vildagliptin group, significant decrease of the serum PAI-1 level by 16.3% (p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2014.11.044